BENGALURU: SigTuple, a Bengaluru-based medtech startup, has successfully raised $4 million (INR 33 crores) in an extended Series C funding round led by SIDBI Venture Capital. The round also saw participation from existing investors including Endiya Partners and strategic leaders from the healthcare sector. This latest injection of funds brings SigTuple’s total funding to $50 million since its founding in 2015.
The fresh capital will be directed towards expanding SigTuple’s geographic reach, broadening its product offerings, and supporting regulatory approvals. SigTuple, founded by Rohit Kumar Pandey, Tathagato Rai Dastidar, and Apurv Anand, has made notable advancements in digital pathology with its flagship product, AI100. This AI-powered solution automates manual microscopic reviews and has gained significant traction in India, Southeast Asia, the Middle East, and North Africa.
In September 2023, AI100 achieved a major milestone by receiving 510(k) clearance from the US FDA, making SigTuple the third global company and the first from India to receive this for AI-assisted digital hematology. Looking ahead, SigTuple plans to launch two major new products in 2024, including a next-generation device for automating all manual microscopy and a point-of-care device using microfluidic technology.
Founder & CEO Tathagato Rai Dastidar expressed excitement about the new funding and product developments, which aim to establish SigTuple as a global leader in diagnostic innovation. The company’s growth aligns with broader trends in AI healthcare advancements, with significant investments from tech giants like Google, Microsoft, and Oracle.